Short Summary
Guardant Health settled its digital sequencing patent dispute with Foundation Medicine for $25 million plus royalties, granting a non‑exclusive license and dismissing all related litigation.
Detailed Summary
In a January 2022 press release, Guardant Health announced a settlement with Foundation Medicine that resolves all pending litigation over Guardant’s digital sequencing technology patents. Under the agreement, Foundation Medicine will pay $25 million and future royalties, while Guardant grants a non‑exclusive license to a defined subset of its patents. The settlement is presented as validation of Guardant’s scientific discoveries and its strong intellectual property portfolio, and it results in the dismissal of all related lawsuits, including the IPR filed by Tempus AI.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Tempus AI, Inc. vs Guardant Health Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Medtronic, Inc.vsMoskowitz Family LLC
Medtronic has filed an IPR petition challenging claim 43 of U.S. Patent 9,005,293, asserting that the claim is anticipated or obvious over prior‑art spinal‑implant references. The petition highlights alleged nondisclosure of key references during prosecution and deficiencies in the patent’s written description.
Tesla, Inc.vsIntellectual Ventures II
Tesla successfully petitioned to challenge Intellectual Ventures II's '670 Patent under Section 103, leading the PTAB to grant institution. The Board found reasonable likelihood of unpatentability based on prior art references Wallen and Berggren regarding LTE/MTC communication systems.
Micron Technology Inc. et al.vsPalisade Technologies, LLP
Micron’s attempt to overturn a DRAM‑related patent is rebuffed as the PTAB finds its Director Review requests introduce prohibited new evidence and deceptive arguments. Patent Owner urges denial of the requests.
NIUM PTE. LTD.vsIntercurrency Software LLC
NIUM PTE. LTD. and Intercurrency Software LLC jointly moved to terminate IPR2025-01586 after reaching a confidential settlement over a foreign‑exchange trading patent.
Ciena CorporationvsK.Mizra LLC
Ciena Corporation seeks Director Review of a USPTO discretionary denial of its IPR on patent 8,782,282, alleging violations of statutory and procedural requirements.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.